ORBIMED ADVISERS INC /CT Form SC 13G August 10, 2001

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G Under the Securities Exchange Act of 1934

Alexion Pharmaceuticals, Inc.
(Name of Issuer)

Common Stock (Title of Class of Securities)

015351109 (CUSIP Number)

August 10, 2001

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- [x] Rule 13d-1(b)
- [x] Rule 13d-1(c)
- [] Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 17252Y104

Names of Reporting Persons.
 I.R.S. Identification Nos. of above persons (entities only).

OrbiMed Advisors Inc.

- 2. Check the Appropriate Box if a Member Of a Group (See Instructions)
 - [] (a)
 - [] (b)

- 3. SEC Use Only
- 4. Citizenship or Place of Organization

Delaware

5. Sole Voting Power 0

Number of

Shares 6. Shared Voting Power 950,000

Beneficially

Owned by 7. Sole Dispositive Power 0

Each Reporting

Person With 8. Shared Dispositive Power 950,000

- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 950,000
- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
- 11. Percent of Class Represented by Amount in Row (9) 5.25%
- 12. Type of Reporting Person (See Instructions) IA

CUSIP No. 17252Y104

Names of Reporting Persons.
 I.R.S. Identification Nos. of above persons (entities only).

OrbiMed Advisors LLC

- 2. Check the Appropriate Box if a Member of a Group (See Instructions)
 - [] (a)
 - [] (b)
- 3. SEC Use Only
- 4. Citizenship or Place of Organization

Delaware

5. Sole Voting Power 0

Number of

Shares 6. Shared Voting Power 950,000

Beneficially

Owned by 7. Sole Dispositive Power 0

Each Reporting

Person With 8. Shared Dispositive Power 950,000

- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 950,000
- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
- 11. Percent of Class Represented by Amount in Row (9) 5.25%
- 12. Type of Reporting Person (See Instructions) CO

CUSIP No. 17252Y104

Names of Reporting Persons.
 I.R.S. Identification Nos. of above persons (entities only).

Samuel D. Isaly

- 2. Check the Appropriate Box if a Member of a Group (See Instructions)
 - [] (a)
 - [] (b)
- 3. SEC Use Only
- 4. Citizenship or Place of Organization

United States

- 5. Sole Voting Power 0
- Number of

Shares 6. Shared Voting Power 950,000

Beneficially

Owned by 7. Sole Dispositive Power 0

Each Reporting

Person With 8. Shared Dispositive Power 950,000

- 9. Aggregate Amount Beneficially Owned by Each Reporting Person 950,000
- 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
- 11. Percent of Class Represented by Amount in Row (9) 5.25%
- 12. Type of Reporting Person (See Instructions) IN
- Item 1. (a) Issuer: Alexion Pharmaceuticals, Inc.
 - (b) Address: 352 Knotter Drive
 Cheshire, Connecticut 06410

- - (b) Address of Principal Business Offices:

767 Third Avenue, 6th Floor New York, New York 10010

- (c) Citizenship:
 Please refer to Item 4 on each cover sheet for each filing person
- (d) Title of Class of Securities Common stock
- (e) CUSIP Number: 015351109
- Item 3. OrbiMed Advisors Inc. is an investment advisor in accordance withss. 240.13d-1(b)(1)(ii)(E). Not applicable for OrbiMed Advisors LLC or Samuel D. Isaly.
- Item 4. Ownership

Please see Items 5 - 9 and 11 for each cover sheet for each filing separately

- Item 5. Ownership of Five Percent or Less of a Class Not Applicable
- Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Reporting persons acquired beneficial ownership of 5.25% of the securities on behalf of Other persons who have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

See Exhibit 2.1.

- Item 8. Identification and Classification of Members of the Group Not Applicable
- Item 9. Notice of Dissolution of Group

Not Applicable

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: August 10, 2001

OrbiMed Advisors Inc.

By: /s/ Samuel D. Isaly
----Name: Samuel D. Isaly

Title: President

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: August 10, 2001

OrbiMed Advisors LLC

By: /s/ Samuel D. Isaly

Name: Samuel D. Isaly Title: Managing Member

Samuel D. Isaly

By: /s/ Samuel D. Isaly

Name: Samuel D. Isaly

EX-1.1 OTHERDOC
2
0002.txt
JOINT FILING AGREEMENT

Exhibit 1.1

JOINT FILING AGREEMENT

The undersigned hereby agree that the Statement on Schedule 13G, dated August 10, 2001, (the "Schedule 13G"), with respect to the Common Stock, \$.0001 par value, of Alexion Pharmaceuticals, Inc. is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to the Schedule 13G and each such amendment. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 10th day of August, 2001.

OrbiMed Advisors Inc.

By: /s/ Samuel D. Isaly

Name: Samuel D. Isaly
Title: President

OrbiMed Advisors LLC

By: /s/ Samuel D. Isaly

Name: Samuel D. Isaly Title: Managing Member

EX-2.1 OTHERDOC Statement of Control Person

Exhibit 2.1

Statement of Control Person

The Statement on Schedule 13G dated August 10, 2001 with respect to the common stock, \$.0001 par value, of Alexion Pharmaceuticals, Inc. is filed by Samuel D. Isaly in accordance with the provisions of Rule 13d-1(c) and Rule 13d-1(k) respectively as a control person (HC) of Orbimed Advisors LLC and Orbimed

Advisors Inc.

Orbimed Advisors Inc. files this statement on Schedule 13G in accordance with the provisions of Rule 13d-1(b) and Rule 13d-1(k) respectively as an investment advisor (IA) and Orbimed Advisors LLC files this statement on Schedule 13G in accordance with the provisions or Rule 13d-1(c) and 13d-1(k) respectively as a corporation (CO).